These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 28534160)

  • 21. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic spectrum of low density lipoprotein receptor gene variations in South Indian population.
    ArulJothi KN; Suruthi Abirami B; Devi A
    Clin Chim Acta; 2018 Mar; 478():28-36. PubMed ID: 29269200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations.
    Hayat M; Kerr R; Bentley AR; Rotimi CN; Raal FJ; Ramsay M
    PLoS One; 2020; 15(2):e0229098. PubMed ID: 32084179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia.
    Iacocca MA; Wang J; Sarkar S; Dron JS; Lagace T; McIntyre AD; Lau P; Robinson JF; Yang P; Knoll JH; Cao H; McPherson R; Hegele RA
    Can J Cardiol; 2018 Oct; 34(10):1316-1324. PubMed ID: 30269829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A combined LDL receptor/LDL receptor adaptor protein 1 mutation as the cause for severe familial hypercholesterolemia.
    Soufi M; Rust S; Walter M; Schaefer JR
    Gene; 2013 May; 521(1):200-3. PubMed ID: 23510778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic and molecular architecture of familial hypercholesterolemia.
    Abifadel M; Boileau C
    J Intern Med; 2023 Feb; 293(2):144-165. PubMed ID: 36196022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?
    Page MM; Bell DA; Watts GF
    Clin Genet; 2020 Apr; 97(4):543-555. PubMed ID: 31833051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Shifting the LDL-receptor paradigm in familial hypercholesterolemia: novel insights from recent kinetic studies of apolipoprotein B-100 metabolism.
    Barrett PH; Watts GF
    Atheroscler Suppl; 2002 Mar; 2(3):1-4. PubMed ID: 11923121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
    Robinson JG
    J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characterization of familial hypercholesterolemia in Spain.
    Palacios L; Grandoso L; Cuevas N; Olano-Martín E; Martinez A; Tejedor D; Stef M
    Atherosclerosis; 2012 Mar; 221(1):137-42. PubMed ID: 22244043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic heterogeneity of autosomal dominant hypercholesterolemia in Mexico.
    Robles-Osorio L; Huerta-Zepeda A; Ordóñez ML; Canizales-Quinteros S; Díaz-Villaseñor A; Gutiérrez-Aguilar R; Riba L; Huertas-Vázquez A; Rodríguez-Torres M; Gómez-Díaz RA; Salinas S; Ongay-Larios L; Codiz-Huerta G; Mora-Cabrera M; Mehta R; Gómez Pérez FJ; Rull JA; Rabès JP; Tusié-Luna MT; Durán-Vargas S; Aguilar-Salinas CA
    Arch Med Res; 2006 Jan; 37(1):102-8. PubMed ID: 16314194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of gene- and cell-based therapies for familial hypercholesterolemia.
    Hajighasemi S; Mahdavi Gorabi A; Bianconi V; Pirro M; Banach M; Ahmadi Tafti H; Reiner Ž; Sahebkar A
    Pharmacol Res; 2019 May; 143():119-132. PubMed ID: 30910740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The study of familial hypercholesterolemia in Italy: A narrative review.
    Bertolini S; Pisciotta L; Fasano T; Rabacchi C; Calandra S
    Atheroscler Suppl; 2017 Oct; 29():1-10. PubMed ID: 28965614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational screening in the LDLR gene among patients presenting familial hypercholesterolemia in the Southeast of Brazil.
    Molfetta GA; Zanette DL; Santos JE; Silva WA
    Genet Mol Res; 2017 Aug; 16(3):. PubMed ID: 28873201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic testing of familial hypercholesterolemia in a real clinical setting.
    Vohnout B; Gabcova D; Huckova M; Klimes I; Gasperikova D; Raslova K
    Wien Klin Wochenschr; 2016 Dec; 128(23-24):916-921. PubMed ID: 27542166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies.
    Ooi EM; Barrett PH; Watts GF
    Int J Cardiol; 2013 Oct; 168(3):1811-8. PubMed ID: 23907036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cosegregation of serum cholesterol with cholesterol intestinal absorption markers in families with primary hypercholesterolemia without mutations in LDLR, APOB, PCSK9 and APOE genes.
    Baila-Rueda L; Pérez-Ruiz MR; Jarauta E; Tejedor MT; Mateo-Gallego R; Lamiquiz-Moneo I; de Castro-Orós I; Cenarro A; Civeira F
    Atherosclerosis; 2016 Mar; 246():202-7. PubMed ID: 26802983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.